What will be the medical insurance reimbursement policy for Upadacitinib in 2025?

Upadacitinib (Upadacitinib), as a selective JAK inhibitor, has been approved in China for the treatment of various autoimmune diseases and has been officially included in the Class B medical insurance catalog. However, the reimbursement policy is strictly limited to patients who meet the indications. According to the national medical insurance policy, upadatinib only provides reimbursement for second-line treatment of patients with specific disease types, including patients aged 12 and above with refractory or moderately severe atopic dermatitis, adult patients with active psoriatic arthritis, and adult patients with moderately to severe active rheumatoid arthritis (RA). In these indications, patients need to be evaluated for ineffectiveness or poor tolerability of first-line or conventional treatments before they can obtain upadatinib through medical insurance reimbursement.

In addition, upadatinib is also covered by medical insurance in the treatment of inflammatory bowel disease, including adult patients with moderately to severely active ulcerative colitis and Crohn's disease who have failed to respond to, are poorly tolerated, or are contraindicated with one or moreTNF inhibitors. For patients with spondyloarthropathy, coverage includes adults with active radiologically negative axial spondyloarthritis (nr-axSpA) and an inadequate response to NSAIDs, and adults with active ankylosing spondylitis (AS, radiologically positive) who have an inadequate response to or intolerance to TNF inhibitors.

In clinical practice, medical insurance reimbursement policies provide significant financial support to patients, but also require strict compliance with indications and treatment procedures. Before using Upatinib, patients need to have a professional doctor evaluate their condition, previous treatment effects and tolerance to ensure they meet the medical insurance conditions. At the same time, doctors and medical institutions will assist in completing the necessary reimbursement information and application processes to ensure that patients can obtain medical insurance support during long-term medication, thereby reducing the financial burden and improving the continuity and compliance of disease management.

Reference materials:https://www.rinvoq.com/